Method of Treating Cancer
US-2019091215-A1 · Mar 28, 2019 · US
Compounds for the treatment of kinase-dependent disorders
US11542259B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11542259-B2 |
| Application number | US-201916964330-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 25, 2019 |
| Priority date | Jan 26, 2018 |
| Publication date | Jan 3, 2023 |
| Grant date | Jan 3, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound which is: or a pharmaceutically acceptable salt thereof. 2. A compound which is 1-N′-(4-fluorophenyl)-1-N-[4-[7-methoxy-6-(methylcarbamoyl)quinolin-4-yl]oxyphenyl]cyclopropane-1,1-dicarboxamide or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Quinolines; Isoquinolines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11542259B2 cover?
- Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides m…
- Who is the assignee on this patent?
- Exelixis Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D215/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).